ADVAIR DISKUS® 250/50
Sponsors
Respirent Pharmaceuticals Co Ltd.
Conditions
Bioequivalence
Phase 1
A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
CompletedNCT04462822
Start: 2020-08-24End: 2020-12-31Updated: 2021-01-20
Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
NCT05982990
Start: 2023-08-01End: 2023-11-20Updated: 2023-08-31